Evidence map›Paper›PMID 38970207›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Enantioselective Aminosilylation of Alkenes by Palladium/Ming-Phos-Catalyzed Tandem Narasaka-Heck/Silylation Reaction.

Kangning Cao, Jie Han, Wenshao Ye, Dejun Hu, Zihao Ye, Junfeng Yang, Junliang Zhang, Fener Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kangning CaoEngineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University Shanghai, Shanghai, 200433, China.
Jie HanSchool of Chemical & Environmental Science, Shaanxi University of Technology, Hanzhong, 723001, China.
Wenshao YeDepartment of Chemistry, Fudan University 2005 Songhu Road, Shanghai, 200438, China.
Dejun HuDepartment of Chemistry, Fudan University 2005 Songhu Road, Shanghai, 200438, China.
Zihao YeDepartment of Chemistry, Fudan University 2005 Songhu Road, Shanghai, 200438, China.
Junfeng YangDepartment of Chemistry, Fudan University 2005 Songhu Road, Shanghai, 200438, China.
Junliang ZhangDepartment of Chemistry, Fudan University 2005 Songhu Road, Shanghai, 200438, China.ORCID https://orcid.org/0000-0002-4636-2846
Fener ChenEngineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University Shanghai, Shanghai, 200433, China.

Funding

National Key R&D Program of China 2021YFF0701600NSFC 21921003NSFC 22031004NSFC 22271053Shanghai Municipal Education Commission 20212308STCSM 21ZR1445900
6 · The paper itself

Abstract

A Pd-catalyzed enantioselective aminosilylation of alkenes via tandem Aza-Heck/silylation reaction under Pd/Sadphos catalysis is disclosed. A wide array of oxime esters and silicon reagents are tolerated, furnishing the chiral pyrrolines bearing one quaternary or two contiguous stereocenters in good yield with high enantioselectivity. Not only terminal alkenes but also tri-substituented internal alkenes successfully participate in the reaction, delivering vicinal stereocenters in complete diastereoselectivity and high enantioselectivity. DFT study is conducted to probe the reaction pathway and the origin of the enantioselectivity, which revealed that the stereoinduction arises from the weak interaction between the aromatic ring of the substrate fragment and naphthyl group in the ligand.

Indexed as

asymmetric catalysisAza‐HeckDFTpalladiumpyrrolines

Identifiers

PMID38970207
PMCPMC11425962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.